Purpose: Mouse models are useful for glaucoma research, but it is unclear 2 whether intraocular pressure (IOP) regulation in mice operates through 3 mechanisms similar to those in humans. Our goal was to determine whether 4 pharmacological compounds that affect conventional outflow facility in human 5 eyes exert similar effects in C57BL/6 mice. 6
Introduction

1
Mice provide important models for glaucoma research, due to their genetic 2 malleability and the extensive catalog of molecular tools that may be exploited to 3 investigate disease mechanisms 1 . While most glaucoma research involving mice 4 has focused on the effect of elevated intraocular pressure (IOP) on the optic 5 nerve, a small but growing community [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] has begun using mice to investigate the 6 physiology of aqueous humor outflow, with the aim to better understand the 7 mechanisms of IOP regulation. In fact, recent data show that the morphology and 8 behavior of the murine conventional outflow pathway is more similar in some 9 ways to humans than are non-human primates (e.g., like humans conventional outflow facility 4, 10 in mice without any detectible effects on 18 unconventional outflow 4, 10 , unlike the response in human eyes where latanoprost 19 increases both conventional 18 and unconventional outflow 19 . This suggests that 20 the physiology and pharmacology of aqueous humor outflow may differ 21 substantially between mice and humans, and should be carefully examined 1 before accepting the mouse as a reliable model for human IOP regulation. 2
The goal of this project was to determine whether pharmacological 3 compounds that are known to affect conventional outflow facility in human eyes 4 exert similar effects on conventional outflow facility in C57BL/6 mice. We 5 specifically examined the facility response to two G-protein coupled receptor 6 agonists, sphingosine 1-phosphate (S1P) and the prostanoid EP 4 agonist 3,7-7 dithia PGE 1 , that respectively decrease 20 and increase 21 outflow facility in human 8 eyes. By comparing the facility response measured in enucleated murine eyes 9 against previous reports in enucleated human eyes 20, 21 , we aimed to determine 10 whether C57BL/6 mice mimic aspects of human conventional outflow pathway 11 pharmacology, which would identify this strain as a promising animal model for 12 S1P and EP4-based regulation of IOP as occurs within human eyes. We also 13 examined whether the pharmacological response is affected by prolonged post-14 mortem times, which is an important consideration for using the mouse model as 15 a research tool when doing ex vivo perfusions.
Methods
1
All experiments were performed using ex vivo tissue and were done in 2 compliance with the ARVO Statement for the Use of Animals in Ophthalmic and 3
Vision Research. 4 Ex Vivo Mouse Eye Perfusion 5
C57BL/6 mice of either sex, aged 8-15 weeks, were killed by cervical 6 dislocation. Eyes were enucleated within 10 minutes of death and perfused 7 immediately or stored in phosphate buffered saline (PBS) at 4°C for 2-3 hours. 8
For perfusion, each eye was mounted on a single well of a 96-well Stripwell plate 9 (Corning) using cyanoacrylate glue to affix the extraocular muscles to the plastic 10 sidewalls of a well. Special attention was given to maintain hydration throughout 11 the experiment by covering the eye with tissue paper that was kept moist by 12 regular drops of PBS. The perfusion solution was Dulbecco's PBS including 13 divalent cations and 5.5 mM glucose (referred to as "DBG") filtered through a 14 0.22 µm filter before use. All perfusions were done at room temperature, with a 15 post hoc correction to account for the viscosity difference between room and 16 physiologic temperature 11, 22 . 17
Our perfusion method follows previously described techniques 11 . Briefly, a 18 33-gauge needle was used to cannulate the anterior chamber under a 19 stereomicroscope using a micromanipulator. The needle was connected via rigid 20 pressure tubing to a glass syringe (25 µL, Hamilton GasTight) placed on the rack 21 of a motorized syringe pump (Pump33; Harvard Apparatus) under computer 22 control. A pressure transducer (142PC01G, Honeywell) monitored IOP through a 1 three-way connector placed in the perfusion line. Custom written LabVIEW 2 software 23 was used to automatically vary the flow rate from the syringe pump to 3 maintain the eye at a user-defined IOP. Eyes were perfused at sequential 4 pressure steps of 4, 8, 15, and 25 mmHg; we refer to this as our "standard 5 perfusion regimen." Eyes were typically perfused for 20 minutes at each pressure 6
step to obtain at least 10 minutes of stable perfusion data, and an average stable 7 flow rate was calculated at each pressure step (Fig. 1 ). Data were considered 8 acceptable if a stable flow rate was achieved in at least 3 of the 4 pressure steps. 9
Based on this criterion, we rejected 12 eyes out of 88 valid perfusions. Selected 10 eyes were fixed by removing the perfusion needle and immediately immersing 11 the eye in 4% paraformaldehyde (PFA) in isotonic saline for 1 hour, followed by 12 long-term storage in 0.1% PFA. For histology, eyes were processed for paraffin 13 embedding, sectioned and stained using hematoxylin and eosin. 14
Outflow Facility Analysis 15
We calculated a pressure-dependent or "conventional outflow facility" (C) 16 by fitting our pressure-flow rate data to the modified Goldmann equation venous pressure is zero (appropriate for enucleated eyes); (ii) F reaches 22
equilibrium at each value of IOP; and (iii) C and F u are independent of IOP. The 1 values of C and F u are defined as the slope and intercept, respectively, of the 2 best-fit linear regression to our measured F versus IOP data (Fig. 1B) . In 3 principle, C would be consistent with values obtained from a 2-level 4 perfusion 3, 4, 6, 7, 25 , except that the additional pressure steps give a much stronger 5 confidence for estimating C 8, 10 . Both C and F u were multiplied by a factor of 1.38 6 to account for viscosity differences between physiologic and room temperatures, 7 as previously described 11, 22 . 8
Experimental Design 9
We conducted three sets of perfusion experiments to measure how 10 conventional outflow facility in the mouse eye responded to receptor-mediated 11 compounds known to affect conventional outflow in human eyes. Experiments 12 used paired eyes (treated vs. untreated contralateral controls), except for cases 13 where data from one eye were rejected based on the stability criterion described 14 above. Paired eyes were perfused sequentially (one eye immediately after 15 enucleation, the contralateral eye 2-3 hrs after enucleation), where we 16 randomised whether the control or experimental eye was perfused first. We also 17 examined whether prolonged post-mortem time (24 hrs storage after enucleation 18 at 4°C) affected the pharmacologic response between paired eyes. 19
In the first set of experiments (Group A), we examined the effect of 20 sphingosine 1-phosphate (S1P), a bioactive lipid that decreases outflow facility 21 by 31% in porcine eyes 26 and 36% in human eyes 20 . Experimental eyes were 22 perfused with 5 µM S1P in DBG containing fatty acid free bovine serum albumin 1 (FAF-BSA; 2 mg/mL; Sigma-Aldrich A8806) and 17 µM sodium hydroxide 2 (NaOH), while control eyes received DBG and FAF-BSA alone without S1P or 3 NaOH. Independent studies demonstrated that 17 µM NaOH had a negligible 4 effect on the pH of DBG (7.137±0.031 vs. 7.107±0.012 for Dulbecco's PBS with 5 or without 17 µM NaOH, respectively, N = 3 independent trials each, p = 0.23; 6
Student's t-test), and therefore NaOH was not included in the control solution. 7 S1P (CAS 26993-30-6 from Sigma-Aldrich, UK) was dissolved from powder into 8 10 mM NaOH in water to give a 3 mM S1P stock solution that was stored 9 at -20°C. Prior to cannulation, each needle was backfilled from the tip with 10 150 µL of the appropriate perfusion solution, a volume sufficient to last several 11 hours even at the highest measured flow rates (~0.3 µL/min). The experimental 12 eye was pre-treated with S1P-containing solution from a reservoir at 8 mmHg for 13 45 minutes to expose the outflow pathway to the drug prior to the start of the 14 standard perfusion regimen. Control eyes were perfused from a reservoir for the 15 same time with solution without S1P. Data from 14 individual eyes (8 S1P-treated 16 and 6 controls, containing 6 pairs) passed the stability criterion and were 17 included in Group A. 18
The aim of the second set of experiments (Group B) was to investigate the 19 role of S1P 1 and S1P 2 receptors in mediating the S1P response. Following a 20 previous study in human eyes 27 , we used W146 (Avanti Polar Lipids) or JTE-013 21 (Cayman Chemical) that are selective antagonists to S1P 1 or S1P 2 receptors, 22
respectively. W146 was dissolved in water as a 1 mM stock solution containing 23 10.6 mM cyclodextrin and 100 mM sodium carbonate (Na 2 CO 3 ) as vehicle, and 1 was stored at -20°C. JTE-013 was dissolved in DMSO as a 1 mM stock solution 2 and stored at -20°C. Experimental eyes were pre-treated with antagonist and 3 S1P-containing solution (45 minutes at 8 mmHg from a reservoir) followed by 4 perfusion with the same solution over the standard perfusion regimen. For W146-5 treated experimental eyes, the perfusion solution contained 5 µM W146 in DBG + 6 5 µM S1P + 2 mg/mL FAF-BSA + 17 µM NaOH + 53 µM cyclodextrin + 500 µM 7 Na 2 CO 3 . For JTE-treated experimental eyes, the perfusion solution contained 8 5 µM JTE-013 in DBG + 5 µM S1P + 2 mg/mL FAF-BSA + 17 µM NaOH + 9 70 mM DMSO. Antagonist concentrations (5 µM) were chosen to be consistent 10 with concentrations used in prior perfusion studies with porcine and human 11 ). Control eyes were perfused with 5 µM S1P in 13 DBG + 2 mg/mL FAF-BSA + 17 µM NaOH, without antagonist, cyclodextrin, 14 Na 2 CO 3 or DMSO vehicle and without pre-treatment. Data from 8 eyes were 15 included in the JTE study (4 JTE-treated and 4 controls, containing 4 pairs), and 16 data from 7 eyes were included in the W146 study (3 W146-treated and 4 17 controls, containing 3 pairs). 18
To account for possible vehicle effects caused by cyclodextrin, Na 2 CO 3 or 19 DMSO, we repeated the W146 and JTE-013 antagonist studies using the same 20 vehicle formulations in the control eyes. For these studies, the control eyes from 21 the W146 study received 5 µM S1P in DBG + 2 mg/mL FAF-BSA + 17 µM NaOH 22 + 53 µM cyclodextrin + 500 µM Na 2 CO 3 , while the experimental eyes from the 23 W146 study received the same solution with 5 µM W146. The control eyes from 1 the JTE study received 5 µM S1P in DBG + 2 mg/mL FAF-BSA + 17 µM NaOH, 2 + 70 mM DMSO, while the experimental eyes from the JTE study received the 3 same solution with 5 µM JTE-013. Both control and experimental eyes were 4 pretreated with perfusion solution for 45 minutes at 8 mmHg from a reservoir 5 prior to starting the standard perfusion regimen. Data from 7 eyes were included 6 in the JTE vehicle-controlled study (3 JTE-treated and 4 controls, containing 3 7 pairs), and data from 7 eyes were included in the W146 vehicle-controlled study 8 (4 W146-treated and 3 controls, containing 3 pairs). 9
In an additional 10 eyes (3 pairs and 4 unpaired eyes), we examined the 10 influence of JTE antagonist alone on outflow facility. For these studies, 11 experimental eyes were perfused with 5 µM JTE-013 + 70 mM DMSO in DBG 12 without FAF-BSA (N = 5 eyes), while the control eyes were perfused with DBG 13 alone without JTE, DMSO, or FAF-BSA (N = 5) using the standard perfusion 14 regimen. Because 70 mM DMSO was found not to affect the facility response in 15 JTE-treated eyes in the presence of S1P (see below), it was not included in the 16 perfusion solution for the control eyes. 17
In the third set of experiments (Group C), we examined the influence of 18 prostaglandin EP 4 receptor activation on conventional outflow in the mouse eye 19 by perfusion with 3,7-dithia PGE 1 , a highly selective PG-EP 4 receptor agonist . Data examining the effects of 3,7-6 dithia PGE 1 included 13 eyes (7 treated and 6 untreated control eyes, containing 7
pairs). 8
In an additional 10 eyes (including 4 pairs and 2 unpaired eyes), we 9 examined whether the response to 3,7-dithia PGE 1 was affected by post-mortem 10 time. For these studies, eyes were enucleated and stored for 24 hrs at 4°C in 11 Dulbecco's modified Eagle's medium (DMEM) and then perfused with 10 nM 3,7-12 dithia PGE 1 in DBG + 17 µM ethanol (N = 6) or with DBG + 17 µM ethanol 13 (N = 4) using the standard perfusion regimen. We chose to examine the post-14 mortem facility response to 3,7-dithia PGE 1 , rather than to S1P, for two reasons. 15
First, 3,7-dithia PGE 1 causes a larger change in outflow facility compared to S1P 16 (e.g., 69% increase following 3,7-dithia PGE 1 21 versus 36% decrease following 17 S1P 20 in human eyes, respectively), and therefore 3,7-dithia PGE 1 would provide 18 a more conservative test to detect smaller differences in facility that might occur 19 with prolonged post-mortem times. Second, 3,7-dithia PGE 1 is an exogenous 20 compound (unlike S1P) and is therefore more representative of potential 21 candidate drugs that may affect conventional outflow. Therefore, by looking at 22 how the facility response to 3,7-dithia PGE 1 changes with post-mortem time, we 23 can gain some insight into how post-mortem time may affect the interpretation of 1 drug efficacy in perfusion experiments (that often incorporate eyes with post-2 mortem times up to 24 hours or use transgenic models where eyes are shipped 3 overnight between laboratories). 4
Statistical Methods 5
All experiments included in this study contained some portion of unpaired 6 eyes caused by one eye of a pair failing to pass the stability criterion. To analyze 7 our data, we performed two statistical analyses: (i) a Welch's t-test that included 8 the full set of eyes (accounting for unequal sample sizes); and (ii) a paired, 2-9 tailed Student's t-test that included only the subset of paired contralateral eyes. 10
Wherever appropriate, we indicate whether a paired Student's t-test or a Welch's 11 t-test was performed. The statistical significance threshold was taken to be a p-12 value of 0.05. 13
All facility values quoted in the text were temperature-corrected to account 14 for viscosity differences, as described above. Figures showing flow rate data, 15 however, were not corrected and represent the true flow rate output from the 16 syringe pump. 17
Results
1
Group A, S1P Decreases Conventional Outflow Facility in Mice 2
Perfusion with 5 µM S1P caused a reduction in flow rate at each perfusion 3 pressure (Fig. 1A) . Compiling data from all eyes revealed a linear relationship 4 between flow rate and IOP (Fig. 1B) , consistent with the modified Goldmann 5 equation (Eq. 1). In response to S1P, conventional outflow facility (C; slope of the 6 linear regression) decreased by 38.9 ± 24.2% (mean ± SD; p = 0.029, paired 7
Student's t-test, N = 6 pairs) compared to paired contralateral eyes perfused 8 without S1P. After temperature correction, conventional outflow facility was 9 0.0125 ± 0.0037 and 0.0073 ± 0.0035 µL/min/mmHg for control and S1P-treated 10 eyes (p = 0.024, Welch's t-test, N = 8 S1P-treated eyes and 6 controls), 11 respectively. We observed no statistical difference in the intercept of the linear 12 regression in response to S1P in either paired (p = 0.71) or unpaired analyses 13 (p = 0.56, Welch's t-test). We observed no obvious differences in the morphology 14 of the trabecular meshwork or Schlemm's canal following treatment with S1P 15 (Fig. 2) . 16
Group B, The S1P 2 Receptor Mediates the S1P Response 17
To determine which receptor mediates the S1P response measured in 18
Group A, we perfused contralateral eyes with either S1P or S1P in combination 19 with either an antagonist to the S1P 2 receptor (5 µM JTE-013; Fig. 3A ) or an 20 antagonist to the S1P 1 receptor (5 µM W146; Fig. 3B ). In eyes treated with S1P 21 without antagonist, the conventional outflow facility was 0.0074 ± 0.0034 22 µL/min/mmHg (N = 15 control eyes from the JTE and W146 experiments; 23 temperature-corrected), which was similar to the conventional facility measured 1 for S1P-treated eyes in Group A. There was no difference in conventional outflow 2 facility caused by vehicle, either for 70 mM DMSO (0.0072 ± 0.0052 vs. 0.0068 3 ± 0.0017 µL/min/mmHg in S1P-treated control eyes from the JTE studies with or 4 without DMSO, respectively; temperature-corrected; p = 0.90, Welch's t-test, N = 5 4 for each group) or for 53 µM cyclodextrin and 500 µM Na 2 CO 3 6 (0.0078 ± 0.0040 vs. 0.0079 ± 0.0035 µL/min/mmHg in S1P-treated control eyes 7 from the W146 study with or without cyclodextrin + Na 2 CO 3 , respectively; 8 temperature-corrected; p = 0.97, Welch's t-test, N = 3 or 4, respectively). For this 9
reason, we compiled all data with and without vehicle control from the W146 or 10 JTE perfusions with S1P. The compiled data shown in Figures 3A and 3B include 11 15 eyes for the JTE antagonist studies (8 controls + 7 experimentals, including 7 12 pairs) and 14 eyes for the W146 antagonist studies (7 controls + 7 experimentals, 13 including 6 pairs). 14 In eyes perfused with both S1P and JTE, the temperature-corrected 15 conventional facility was 0.0133 ± 0.0019 µL/min/mmHg, nearly 2-fold larger than 16 eyes treated with S1P without antagonist (0.0070 ± 0.0036 µL/min/mmHg; p = 17 0.0012, Welch's t-test , N = 8 S1P vs. 7 S1P + JTE,) and similar to the 18 conventional facility of control eyes from Group A. In contrast, conventional 19 facility was unchanged between eyes perfused with S1P or S1P and W146 20 (0.0079 ± 0.0034 vs. 0.0094 ± 0.0032 µL/min/mmHg; temperature-corrected; p = 21 0.41, Welch's t-test, N = 7 S1P vs. 7 S1P + W146; β = 0.145, α = 0.05, assuming 22
the facility values for S1P-treated and untreated eyes from Group A with N = 7 for 23 each group). These data demonstrate that JTE largely blocks the facility-reducing 1 effect of S1P, while W146 has little effect, suggesting that the S1P 2 receptor, and 2 not the S1P 1 receptor, is principally responsible for mediating the S1P response 3 in C57BL/6 mice. We did not observe significant effects of JTE or W146 in the 4 presence of S1P on the intercept of the pressure-flow relationship (p ≥ 0.27). 5
In eyes perfused with 5 µM JTE without S1P, temperature-corrected 6 conventional facility was nearly 2-fold greater than in untreated control eyes (Fig.  7   3C) , increasing from 0.0096 ± 0.0026 to 0.0194 ± 0.0056 µL/min/mmHg 8 (p = 0.017; N = 5 control and N = 5 JTE-treated eyes, Welch's t-test). There was 9 no significant difference in the intercept of the pressure-flow relationship between 10 JTE-treated and untreated eyes (p = 0.19). These data suggest that endogenous 11 S1P signaling may be regulating conventional outflow facility in the mouse 12 trabecular meshwork, which can be blocked by S1P 2 receptor antagonist JTE-13
14
Group C, EP 4 Receptor Agonist Increases Conventional Outflow Facility in 15
Mice 16
We measured a two-fold increase in conventional outflow facility following 17 perfusion with 10 nM 3,7-dithia PGE 1 (Fig. 4A) , with the temperature-corrected 18 facility increasing from 0.0062 ± 0.0005 to 0.0131 ± 0.0024 µL/min/mmHg 19 (p = 0.0003; Welch's t-test; N = 6 or 7 for untreated eyes or eyes treated with 3,7-20 dithia PGE 1 , respectively). Considering only paired eyes, the conventional facility 21 increased by 105.8 ± 48.4% following 3,7-dithia PGE 1 treatment compared to 22 untreated contralateral eyes (p = 0.02; paired Student's t-test, N = 4 pairs). In 23 contrast, 3,7-dithia PGE 1 inconsistently affected the intercept of the pressure-flow 1 relationship. More specifically, while we observed a statistically detectable 2 decrease in the intercept between treated and untreated groups using unpaired 3 analysis (p = 0.04), we observed no difference using paired analysis (p = 0.31). 4
After 24 hrs post-enucleation and storage at 4°C in DMEM, eyes appeared 5 well preserved with clear corneas and constricted pupils. In contrast, eyes stored 6 for the same period in PBS at 4°C appeared "mushy" with cloudy corneas and 7 dilated pupils. Following 24 hr storage in DMEM, conventional outflow facility in 8 eyes perfused with 3,7-dithia PGE 1 was 0.0128 ± 0.0034 µL/min/mmHg (N = 6 9 eyes; Fig. 4B ), which was significantly larger (p = 0.037, Welch's t-test) than the 10 baseline facility of untreated eyes (0.0087 ± 0.0014 µL/min/mmHg, N = 4 eyes) 11 by unpaired analysis. When considering only paired eyes, the relative facility 12 increase following 3,7-dithia PGE 1 was nearly 3-fold smaller after 24 hrs 13 (38.1 ± 34.5%; N = 4 pairs) versus after 3 hrs (see above) and failed to achieve 14 statistical significance (p = 0.126, paired Student's t-test). Similarly, after 24 hrs 15 for pressures of 8 mmHg and above, there was a tendency for 3,7-dithia PGE 1 to 16 increase the flow rate, but even at 25 mmHg the flow rate increase failed to 17 achieve statistical significance (p = 0.10). This is in contrast to eyes perfused 18 within 3 hrs post-mortem, when 3,7-dithia PGE 1 caused a statistically significant 19 increase in flow rate for all pressures of 8 mmHg or larger (p < 0.05). This 20 suggests that while the facility-increasing effect of 3,7-dithia PGE 1 was present 21 24 hrs after enucleation, the effect was subtle and detectable only when flow 22 rates were measured over several perfusion pressures and linear regression 1 analysis was used to calculate the slope of the flow rate-pressure relationship. 2
Discussion
3
This study demonstrates that C57BL/6 mouse eyes respond to S1P and 4 EP 4 agonist in a similar manner as that previously reported for human eyes. 5
Specifically, S1P decreased murine outflow facility by 39%, which was nearly 6 identical to the 36% decrease previously reported in human eyes 20 . The 7 prostanoid EP 4 agonist, 3,7-dithia PGE 1 , caused a facility increase of 106% in 8 mice, which was somewhat larger than the 69% increase observed in human 9 eyes 21 . Quantitative differences aside, the similarity in qualitative response 10 between species suggests that similar pharmacological signaling mechanisms 11 underlie the facility response to S1P and 3,7-dithia PGE 1 between C57BL/6 mice 12 and human eyes. 13 S1P is known to bind to one of five G protein-coupled receptors (S1P 1-5 ) 14 each of which exhibit different downstream signaling events and are differentially 15 regulated in different tissues 33 . S1P rapidly decreases outflow facility 20, 26 , and 16 lysophospholipids similar to S1P are found in aqueous humor 34 , possibly acting 17 as endogenous regulators of outflow facility 35 . In C57BL/6 mice, we detected 18 expression of S1P 1 and negligible levels of S1P 2 and S1P 3 in Schlemm's canal 19 endothelium by in situ confocal immunofluorescence (Supplemental Figure 1) . 20
The relative absence of S1P 2 and S1P 3 labeling could be attributed to reduced 21 antibody sensitivity compared to prior studies by our group 20 that reported 22 relatively low levels of S1P 2 and S1P 3 expression, compared to S1P 1 , by human 23 Schlemm's canal cells in situ. Despite the seemingly low levels of S1P 2 1 expression, the facility-decreasing effect of S1P in mice was almost completely 2 abolished by JTE-013, an antagonist to the S1P 2 receptor, but not by W146, an 3 antagonist to the S1P 1 receptor. Similar effects were observed in human eyes 27 , 4
where JTE-013 blocked facility reduction as well as phosphorylated myosin light 5 chain (pMLC) in response to S1P, while no blocking effect on pMLC was 6 observed in the presence of either W146 or VPC23019 (a dual antagonist to 7 S1P 1 and S1P 3 ). Perfusion with JTE-013 alone increased conventional outflow by 8 two-fold in C57BL/6 mice, yielding a conventional outflow facility (0.0194 ± 9 0.0056 µL/min/mmHg, N = 5) that was larger than that measured in either 10 untreated eyes (0.0125 ± 0.0037 µL/min/mmHg, N = 6, from Group A; p = 0.056, 11
Welch's t-test) or eyes perfused with 3,7-dithia PGE 1 (0.0131 ± 0.0024 12 µL/min/mmHg, N = 7, from Group C; p = 0.063, Welch's t test). These data 13 strongly implicate the S1P 2 receptor as a key mediator of the facility-regulating 14 effect of S1P and suggest an endogenous concentration of S1P within the 15 trabecular meshwork. It should be noted however, that the selectivity of JTE-013 16 to the S1P 2 receptor has been recently called into question 36, 37 based on data 17
reporting an effect of JTE-013 in S1P 2 knock-out mice Post hoc comparison of facility data revealed that conventional outflow 3 facility was, rather surprisingly, nearly 60% larger in eyes perfused with 0.2% 4 FAF-BSA in DBG compared to eyes perfused with DBG alone. More specifically, 5 there was a statistical difference (p = 0.028, Welsh's t-test) between eyes 6 perfused with 0.2% FAF-BSA from Group A (0.0125 ± 0.0037 µL/min/mmHg, 7 N = 6) compared to eyes perfused without FAF-BSA aggregated from Groups B 8
and C (0.0078 ± 0.0025 µL/min/mmHg, N = 11). FAF-BSA was included as a 9 carrier for S1P in the perfusion medium, following prior studies in human eyes 20 , 10 and therefore FAF-BSA was excluded from experiments that did not contain S1P 11 (i.e., all experiments from Group C and experiments from Group B examining 12 JTE alone). We are not certain as to the cause of this difference, nor were there 13 any obvious differences in the gender, age or genetic background of the mice 14 that could explain this difference. Because elevated FAF-BSA would be expected 15 to decrease (due to possible obstruction), rather than increase, outflow facility 44 , 16 these data may indicate a potential trace contaminant carried from the FAF-BSA 17 source (e.g., lipoprotein, phospholipid or lipopolysaccharide) that may itself 18 increase facility. We observed that the effect of FAF-BSA on facility persisted 19 through two different batches from the supplier (lot numbers 040M7715V and 20 108k7425), suggesting a potential widespread, rather than batch-dependent, 21
contaminant. Nevertheless, because our experiments used a paired perfusion 22 approach, in which we compared the relative effects of selective receptor 23 agonists or antagonists diluted in otherwise identical perfusion solutions (both 1 control and experimental), we conclude that the facility effects we observed were 2 in fact due to drug treatment, and not to the presence or absence of FAF-BSA in 3 the perfusion media. 4
Data from the current study suggest that the fraction of unconventional 5 outflow in mice may be significantly smaller than previously estimated 3,4,6,11
. We 6 calculate the unconventional fraction of total outflow as 7
8
Using the regression parameters from control eyes from Group C (perfused 9 within 3 hrs post-enucleation without FAF-BSA; Fig. 4A ) yields a relative 10 contribution of 37.9 ± 15.6% unconventional to total outflow at 8 mmHg. In 11 contrast, our previous work estimated that unconventional outflow represents 12 66% of total outflow in C57BL/6 mice 11 . This difference is largely attributable to 13 the 5-fold difference in F U between our current study (0.035 ± 0.025 µL/min; 14 temperature-corrected; control eyes of Group C at 3 hrs) and our previous study 15 ). We do not understand the reasons for such a large 18 discrepancy in F U , but it may be related to differences in experimental 19 techniques, and in particular the hydration of the eye, between the two studies. In 20 the current study, the eye was covered with tissue paper that was kept moist by 21 ) and more consistent with 8 the upper range of unconventional outflow estimated in human eyes (46-54%) 46 . 9
This suggests that particular strains of mice (e.g., C57BL/6 or other strains that 10 exhibit similar pharmacological behavior) may serve as better models for the 11 physiology or pharmacology of IOP regulation as occurs within the conventional 12 outflow pathway of human eyes. 13
The conventional outflow pathway is sensitive to post-mortem 14 degradation 47 , and enucleated whole human globes are routinely accepted for 15 perfusion studies up to 24 hrs or longer after death. After 24 hrs post-enucleation 16 and storage in DMEM at 4°C, the facility-increasing effect of 3,7-dithia PGE 1 17 remained statistically detectable in C57BL/6 mouse eyes, but only in the larger 18 data set (unpaired set with 10 eyes) when conventional facility was measured as 19 the slope of the flow rate-pressure relationship. When considering only perfusion 20 data at individual pressures, the flow rate increase caused by 3,7-dithia PGE 1 21 failed to achieve statistical significance at 24 hrs (p ≥ 0.10). This suggests that a 22 24 hr post-mortem delay likely represents an upper limit for detection of 23 pharmacological effects in ex vivo mouse eyes. More to this point, post-hoc 1 analysis of conventional facility in DBG-perfused mouse eyes after 24 hrs 2 (0.0087 µL/min/mmHg, temperature-corrected, from Group C) was approximately 3 40% greater (p = 0.043; Welch's t-test) than the facility measured in eyes within 3 4 hrs after enucleation (0.0062 µL/min/mmHg, temperature-corrected, from Group 5 C). This change in baseline facility explains why the relative facility increase 6 following 3,7-dithia PGE 1 after 24 hrs (38%) was nearly 3-fold less than that 7 measured within 3 hrs (106%). Taken together, these data demonstrate that 8 post-mortem changes occurring within 24 hrs can affect both conventional facility 9 and the relative facility response to pharmacological compounds. We are not 10 aware of any studies that have examined outflow facility as a function of post-11 mortem time in human eyes, but if the post-mortem response of human and 12 mouse eyes are similar, then these data suggest that there may be a 13 considerable loss of sensitivity for detecting pharmacologically-induced changes 14 in outflow facility using human eyes even at 24 hrs post-mortem. 15
In conclusion, we demonstrate that conventional outflow facility in 16 C57BL/6 mice mimics the pharmacological response of human eyes to PG-EP 4 17
and S1P receptor agonists that respectively increase and decrease outflow 18 angle from control (A) and S1P-treated (B) mouse eyes. AC, anterior chamber; 5 TM, trabecular meshwork; SC, Schlemm's canal; I, iris; C, cornea; S, sclera. Bars 6 are 50 µm. The absence of giant vacuoles in the inner wall of Schlemm's canal 7 may reflect the fact that the eyes were fixed by immersion. Figure 1 : Confocal immunofluorescence microscopy of S1P 3 receptor expression in angle tissues of the C57BL/6 mouse eye. Slides 4 containing frozen sections of mouse eyes (10 µm; embedded in OCT) were 5 probed with polyclonal antibodies raised against peptides that correspond to 6 carboxyl terminus of human S1P receptors 1 (sc-25489), 2 (sc-30024) and 3 (sc-7 25491), but cross react with mouse. Binding of primary antibodies to mouse 8 tissues was visualized using goat anti-rabbit antibodies conjugated to Dylight that 9 were excited and fluorescence signals digitally captured by a Leica SP5 confocal 10 microscope. Images from all sections were recorded during the same session 11 using identical confocal settings. As a positive control for tissue quality and 12 localization of Schlemm's canal endothelia (asterisks), slides containing mouse 13 eye sections were probed with monoclonal antibodies that specifically recognize 14 PECAM-1, followed by goat anti-mouse secondary antibodies conjugated to 15
Dylight. As a negative control, some slides containing mouse sections were 16 probed only with goat anti-rabbit antibodies conjugated to Dylight (2). 17 18
